| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6015577 | BOEHRINGER INGELHEIM | Pharmaceutical compositions containing dipyridamole or mopidamol and acetylsalicylic acid or the physiologically acceptable salts thereof, processes for preparing them and their use in treating clot formation |
Jan, 2017
(7 years ago) | |
Aggrenox is owned by Boehringer Ingelheim.
Aggrenox contains Aspirin; Dipyridamole.
Aggrenox has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Aggrenox are:
- US6015577
Aggrenox was authorised for market use on 22 November, 1999.
Aggrenox is available in capsule, extended release;oral dosage forms.
Aggrenox can be used as to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis.
The generics of Aggrenox are possible to be released after 18 January, 2017.
Drugs and Companies using ASPIRIN; DIPYRIDAMOLE ingredient
Market Authorisation Date: 22 November, 1999
Treatment: To reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
AGGRENOX family patents
